Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France (SYMBIOSE)

AstraZeneca

Status: Completed

Conditions: Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT00812357

NIS-RFR-SYM-2008/1

Details and patient eligibility

About

Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma

Enrollment: 579 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Asthmatic patients treated for this disease with Symbicort Turbuhaler
• Patients monitored for asthma by the doctor for at least 12 months
• Patients seen in outpatient care at the baseline visit
• Patients agreeing to participate in the study

Exclusion criteria

• Patients with any chronic lower respiratory disease other than asthma
• Patients receiving anti-IgE agents in the last 4 months
• Patients receiving desensitisation treatment outside of the maintenance phase
• Patients deemed to be unable to respond to the study for linguistic or cognitive reasons

Trial design

579 participants in 2 patient groups

1

Description:

Patients treated with Symbicort basic treatment

2

Description:

Patients treated with Symbicort basic treatment + treatment of symptoms as needed